CRNX
Price
$29.96
Change
-$0.45 (-1.48%)
Updated
Jun 27 closing price
Capitalization
2.81B
40 days until earnings call
XENE
Price
$32.40
Change
+$0.20 (+0.62%)
Updated
Jun 27 closing price
Capitalization
2.49B
39 days until earnings call
Interact to see
Advertisement

CRNX vs XENE

Header iconCRNX vs XENE Comparison
Open Charts CRNX vs XENEBanner chart's image
Crinetics Pharmaceuticals
Price$29.96
Change-$0.45 (-1.48%)
Volume$1.64M
Capitalization2.81B
Xenon Pharmaceuticals
Price$32.40
Change+$0.20 (+0.62%)
Volume$13.15M
Capitalization2.49B
CRNX vs XENE Comparison Chart in %
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. XENE commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Buy and XENE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (CRNX: $29.96 vs. XENE: $32.40)
Brand notoriety: CRNX and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 213% vs. XENE: 964%
Market capitalization -- CRNX: $2.81B vs. XENE: $2.49B
CRNX [@Biotechnology] is valued at $2.81B. XENE’s [@Biotechnology] market capitalization is $2.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 2 TA indicator(s) are bullish while XENE’s TA Score has 3 bullish TA indicator(s).

  • CRNX’s TA Score: 2 bullish, 6 bearish.
  • XENE’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, XENE is a better buy in the short-term than CRNX.

Price Growth

CRNX (@Biotechnology) experienced а -1.77% price change this week, while XENE (@Biotechnology) price change was +1.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

CRNX is expected to report earnings on Aug 08, 2025.

XENE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($2.81B) has a higher market cap than XENE($2.49B). XENE YTD gains are higher at: -17.347 vs. CRNX (-41.404). XENE has higher annual earnings (EBITDA): -290.36M vs. CRNX (-373.49M). CRNX has more cash in the bank: 1.27B vs. XENE (550M). XENE has less debt than CRNX: XENE (8.68M) vs CRNX (50.8M). XENE has higher revenues than CRNX: XENE (7.5M) vs CRNX (760K).
CRNXXENECRNX / XENE
Capitalization2.81B2.49B113%
EBITDA-373.49M-290.36M129%
Gain YTD-41.404-17.347239%
P/E RatioN/AN/A-
Revenue760K7.5M10%
Total Cash1.27B550M232%
Total Debt50.8M8.68M586%
FUNDAMENTALS RATINGS
CRNX vs XENE: Fundamental Ratings
CRNX
XENE
OUTLOOK RATING
1..100
6142
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
6745
SMR RATING
1..100
9495
PRICE GROWTH RATING
1..100
6457
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XENE's Valuation (76) in the Biotechnology industry is in the same range as CRNX (92) in the Pharmaceuticals Major industry. This means that XENE’s stock grew similarly to CRNX’s over the last 12 months.

XENE's Profit vs Risk Rating (45) in the Biotechnology industry is in the same range as CRNX (67) in the Pharmaceuticals Major industry. This means that XENE’s stock grew similarly to CRNX’s over the last 12 months.

CRNX's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as XENE (95) in the Biotechnology industry. This means that CRNX’s stock grew similarly to XENE’s over the last 12 months.

XENE's Price Growth Rating (57) in the Biotechnology industry is in the same range as CRNX (64) in the Pharmaceuticals Major industry. This means that XENE’s stock grew similarly to CRNX’s over the last 12 months.

XENE's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for CRNX (100) in the Pharmaceuticals Major industry. This means that XENE’s stock grew significantly faster than CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXXENE
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
85%
Momentum
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
77%
MACD
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
78%
Bullish Trend 3 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
74%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 13 days ago
75%
BollingerBands
ODDS (%)
Bullish Trend 10 days ago
86%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HGXRX16.620.12
+0.73%
Hartford Global Impact R3
GHTRX15.130.10
+0.67%
Goldman Sachs International T/M Eq R6
PARMX39.360.15
+0.38%
Parnassus Mid-Cap
VEXRX105.380.27
+0.26%
Vanguard Explorer Adm
MGZZX19.760.02
+0.10%
Morgan Stanley Inst Global Insgt R6

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
-0.10%
XNCR - CRNX
58%
Loosely correlated
-3.10%
TRDA - CRNX
57%
Loosely correlated
-1.57%
DYN - CRNX
56%
Loosely correlated
-4.78%
IDYA - CRNX
55%
Loosely correlated
-4.13%
RVMD - CRNX
55%
Loosely correlated
-1.52%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+0.62%
IDYA - XENE
56%
Loosely correlated
-4.13%
CRNX - XENE
54%
Loosely correlated
-0.10%
ATXS - XENE
54%
Loosely correlated
N/A
DNLI - XENE
51%
Loosely correlated
-2.69%
IMVT - XENE
50%
Loosely correlated
N/A
More